Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women

Menopause

Volumn 10, Issue 6, 2003, Pages 516-521

  Archer, David F ^a,l   DeAbate, C Andrew ^b   Einhaus, Kathryn B ^c   Heuer, Marvin A ^d   Kirkegarrd, Lance W ^e   Miller, James D ^f   Nguyen, Hoa N ^g   Pasquale, Samuel ^h   Swanson, Stephen G ⁱ   Wade, Ann E ^j   Yankaskas, Mary C ^k  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Medical Research Centers   (United States)

^c Lutheran Senior Health Services   (United States)

^d Women's Research Center Inc   (United States)

^e Hill Top Research   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

^g DEPARTMENT OF COLORECTAL SURGERY   (United States)

^h ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

ⁱ Women's Clinic of Lincoln   (United States)

^j Univ Consortium for Clin Research   (United States)

^k Clinical Physiology Associates Inc   (United States)

^l The Jones Institute for Reproductive Medicine   (United States)

more..

Author keywords

17 Estradiol; Adverse effects; Menopausal symptoms; Percutaneous gel

Indexed keywords

ESTRADIOL; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; GEL; HEADACHE; HOT FLUSH; HUMAN; INFECTION; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MENORRHAGIA; METRORRHAGIA; MULTICENTER STUDY; NAUSEA; PAIN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RASH; UTERUS BLEEDING; VAGINA BLEEDING; VAGINITIS; VASOMOTOR DISORDER; ADRENERGIC SYSTEM; CASE CONTROL STUDY; DRUG EFFECT; ESTROGEN THERAPY; INTRADERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GELS; HOT FLASHES; HUMANS; POSTMENOPAUSE; VASOMOTOR SYSTEM;

EID: 2342642223     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000070526.74726.8A     Document Type: Article

References (21)

1. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-1071.
2. Corson SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int J Fertil 1993;38:79-91.
3. Nachtigall LE. Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Am J Obstet Gynecol 1995;173:993-997.
4. Jewelewicz R. New developments in topical estrogen therapy. Fertil Steril 1997;67:1-12.
5. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-1620.
6. Dupont A, Dupont P, Cusan L, et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991;13:297-311.
7. Laufer LR, DeFazio JL, Lu JK, et al. Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol 1983;146:533-540.
8. Connell EB. Transdermal estrogen therapy. Postgrad Med 1997;101:11-116, 122, 128-130.
9. Foidart JM, Beliard A, Hedon B, et al. Impact of percutaneous estradiol gels in postmenopausal hormone replacement therapy on clinical symptoms and endometrium. Br J Obstet Gynaecol 1997;104:305-310.
10. Jensen J, Riis BJ, Strom V, et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987;156:66-71.
11. Jensen PB, Jensen J, Riis BJ, et al. Climacteric symptoms after oral and percutaneous hormone replacement therapy. Maturitas 1987;9:207-215.
12. Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61-65.
13. Kornafel KL, March CM. Estradiol gel in the treatment of menopausal symptoms: a placebo-controlled double-blind case study of efficacy and safety. South Med J 1992;85:270-273.
14. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001;(1):CD002978. Review.
15. Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561-582.
16. Notelovitz M, Cassel D, Hille D, et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2000;182:7-12.
17. Archer DF, Furst K, Tipping D, et al. A randomized comparison of continuous-combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94:498-503.
18. Asmussen B. Transdermal therapeutic systems - actual state and future developments. Methods Find Exp Clin Pharmacol 1991;13:343-351.
19. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991;100:482-488.
20. Dry SJ, Field CS, Herrmann RR, et al. Effects of long-term transdermal administration of estradiol on serum lipids. Mayo Clin Proc 1998;73:735-738.
21. Sitruk-Ware R. Estrogen therapy during menopause: practical treatment recommendations. Drugs 1990;39:203-217.